ARCHIVES

Ivax Paclitaxel To Remain On Market In Deal With BMS.

This article is from The Cancer Letter archive.

Vol. 28 No. 05 | February 1, 2002

Download PDF Visit The Full Archive

Related Articles

Recombinant Protein C Cuts Risk Of Sepsis Death

February 22, 2002

Zydelig Tablets Approved For Three Blood Cancers

July 25, 2014

Hormone Therapy Can Reduce Survival In Men With Heart Problems

August 26, 2011

In Brief: Robert Bast Succeeds Singleton As Director Of Duke Cancer Center; Robert Bell Deputy

August 14, 1987

New Tenure Program Begins, NIH May Have 20-30 Positions Open

August 5, 1994

West Virginia CCOP Will Be Funded; NASAU Joins Cincinnati As The Two Cut For Slow Patient Accrual

August 31, 1984